How do CRISPR systems edit eukaryotic genomes?

Microbial CRISPR systems were first recognized as repeated DNA sequences by Francisco Mojica University of Alicante and later understood as part of an adaptive immune system in bacteria and archaea. The breakthrough demonstration that RNA-programmed CRISPR nucleases could be repurposed to cut DNA was published by Jennifer Doudna University of California Berkeley and Emmanuelle Charpentier Max Planck Unit for the Science of Pathogens. Shortly thereafter, Feng Zhang Broad Institute and Massachusetts Institute of Technology and others adapted these tools for eukaryotic cells, establishing a practical route to edit genomes across plants, animals, and human cells. The relevance of this technology spans basic research, medicine, and agriculture while raising social and regulatory questions that vary by region and culture.

Mechanism of targeting and cleavage

Editing begins with a programmable guide RNA that directs a CRISPR-associated nuclease to a complementary DNA sequence. Cas9, the most widely used nuclease derived from Streptococcus pyogenes, recognizes a short protospacer adjacent motif near the target and uses base pairing between guide RNA and target DNA to form a DNA-RNA hybrid. The protein then introduces a double-strand break at the specified location. Eukaryotic genome editing relies on this programmable cleavage because the break triggers the cell’s own DNA repair systems. Chromatin structure and DNA methylation in eukaryotic cells influence guide accessibility and can reduce cutting efficiency compared with naked bacterial DNA, so designing guides that account for nucleosome positioning and epigenetic state improves outcomes.

Repair pathways and engineered variants

After cleavage, non-homologous end joining and homology-directed repair determine the editing outcome. Non-homologous end joining is error-prone and often produces small insertions or deletions that can disrupt a gene. Homology-directed repair can incorporate a user-supplied DNA template to install precise changes but is typically less efficient in many somatic cell types. To overcome limitations, researchers developed alternatives such as base editors and prime editors. Base editors engineered by David Liu Harvard University and Broad Institute fuse deaminase enzymes to a catalytically impaired Cas protein to change single bases without creating double-strand breaks. Prime editing further expands precision by combining a reverse transcriptase with a guide RNA that encodes the desired edit.

Delivery, specificity, and consequences

Delivering CRISPR components into eukaryotic cells is central to success and determines both efficiency and safety. Viral vectors including adeno-associated viruses are commonly used for in vivo delivery in therapeutic contexts, while lipid nanoparticles and electroporation are favored for ex vivo editing or delivery to cultured cells. Off-target cuts, immune responses to bacterial proteins, mosaicism in embryos, and unintended edits remain practical and ethical challenges. Environmentally, gene editing in crops or wild populations may affect biodiversity and ecosystem balance, and community engagement is crucial where traditional land stewardship and cultural values intersect with biotechnology. Regulatory frameworks differ markedly among countries, shaping research trajectories and access to therapies. The scientific lineage from Mojica to Doudna and Charpentier to Zhang illustrates rapid translation from discovery to application, but responsible deployment demands ongoing evaluation of risks, societal values, and ecological consequences.